Bionovo To Present Recent Findings Of BZL101, Its Anti-cancer Agent, At The American Association Of Cancer Research

Bionovo, Inc.
(OTC Bulletin Board: BNVI) will present findings on the mechanism of action
of its anti-cancer agent BZL101, which is advancing to Phase 1/2 clinical
testing for late stage breast cancer at the American Association of Cancer
Research (AACR) being held at the Los Angeles Convention Center in Los
Angeles, CA, April 14 - 17, 2007.



Bionovo's poster presentation will describe the pathway for cancer cell
apoptosis (cell death) induced by BZL101 while leaving normal cells
unaffected. As explained by Dr. Emma Shtivelman, Director of Cancer
Research at Bionovo, the ability of BZL101 to induce apoptosis is due to
attenuation of mitochondrial transmembrane potential (MTP) leading to the
release of reactive oxygen species, causing inhibition of glycolysis and
ending with induction of oxidative DNA damage.



A paper on BZL101's mechanism of action and unique selective properties
based on the company's initial Phase 1 clinical trial was published late
last year in the peer-reviewed journal, Breast Cancer Research and
Treatment.



"BZL101's mechanism of action and unique selective properties" said Dr.
Isaac Cohen, President and CEO of Bionovo, "are a result of some of the
biological differences between cancer cells and normal cells. We are hoping
that capitalizing on the difference will result in a safe and effective
treatment for cancer."



Bionovo, Inc.



Bionovo is a drug development company focusing on the discovery of
novel pharmaceutical agents for cancer and women's health. The company has
two drugs in clinical testing. MF101 is in Phase 2 for quality of life
conditions associated with menopause, and BZL101 is in Phase 1/2 for the
treatment of advanced breast cancer. The company has an additional pipeline
of drugs in development for breast cancer, pancreatic cancer and other
menopausal symptoms with a total of 4 drug candidates expected to be in
clinical trials by the end of 2007. The company is developing its products
in close collaboration with leading U.S. academic research centers,
including the University of California, San Francisco, University of
Colorado Health Sciences Center and University of California, Berkeley. For
further information please visit: bionovo.



Forward-Looking Statements



This release contains certain forward-looking statements relating to
the business of Bionovo, Inc. that can be identified by the use of
forward-looking terminology such as "believes," "expects," or similar
expressions. Such forward-looking statements involve known and unknown
risks and uncertainties, including uncertainties relating to product
development, efficacy and safety, regulatory actions or delays, the ability
to obtain or maintain patent or other proprietary intellectual property
protection, market acceptance, physician acceptance, third party
reimbursement, future capital requirements, competition in general and
other factors that may cause actual results to be materially different from
those described herein as anticipated, believed, estimated or expected.
Certain of these risks and uncertainties are or will be described in
greater detail in our filings with the Securities and Exchange Commission,
which are available at sec. Bionovo, Inc. is under no obligation
(and expressly disclaims any such obligation) to update or alter its
forward-looking statements whether as a result of new information, future
events or otherwise.


Bionovo

bionovo